Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Why better prognostic factors for multiple myeloma are needed.

Kyle RA.

Blood. 1994 Apr 1;83(7):1713-6. No abstract available.

PMID:
8142638
[PubMed - indexed for MEDLINE]
Free Article
2.

Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.

Pulkki K, Pelliniemi TT, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R.

Br J Haematol. 1996 Feb;92(2):370-4.

PMID:
8603002
[PubMed - indexed for MEDLINE]
3.

Prognostic factors in multiple myeloma.

Kyle RA.

Stem Cells. 1995 Aug;13 Suppl 2:56-63. Review.

PMID:
8520513
[PubMed - indexed for MEDLINE]
4.

Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.

Kaiser U, Oldenburg M, Jaques G, Auerbach B, Havemann K.

Ann Hematol. 1996 Sep;73(3):121-6.

PMID:
8841099
[PubMed - indexed for MEDLINE]
5.

[The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].

Lubo-Lesnichenko IF, Bessmel'tsev SS, Abdulkadyrov KM, Blinov MN, Stel'mashenko LV.

Ter Arkh. 1996;68(10):28-31. Russian.

PMID:
9026938
[PubMed - indexed for MEDLINE]
6.

Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.

Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, Nielsen JL, Odén A, Seidel C, Waage A, Westin J, Wislöff F.

Br J Haematol. 1999 Sep;106(4):1005-12.

PMID:
10520004
[PubMed - indexed for MEDLINE]
7.

Prognostic factors and staging systems of multiple myeloma:.

Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J.

Chin Med J (Engl). 2007 Oct 5;120(19):1655-8.

PMID:
17935664
[PubMed - indexed for MEDLINE]
Free Article
8.

Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease.

Joshua DE, Brown RD, Gibson J.

Leuk Lymphoma. 1994 Nov;15(5-6):375-81. Review.

PMID:
7873994
[PubMed - indexed for MEDLINE]
9.

Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis?

Boccadoro M, Gallone G, Frieri R, Pileri A, Bataille R, Klein B.

Blood. 1993 Dec 1;82(11):3507-8. No abstract available.

PMID:
8241520
[PubMed - indexed for MEDLINE]
Free Article
10.

A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.

Lauta VM.

Cancer. 2003 May 15;97(10):2440-52. Review.

PMID:
12733143
[PubMed - indexed for MEDLINE]
Free Article
11.

Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.

Diem H, Fateh-Moghadam A, Lamerz R.

Clin Investig. 1993 Nov;71(11):918-23.

PMID:
8312685
[PubMed - indexed for MEDLINE]
12.

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M.

Bone Marrow Transplant. 1999 Sep;24(5):497-503.

PMID:
10482933
[PubMed - indexed for MEDLINE]
Free Article
13.

The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma.

Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K, Kyriakou DS.

Clin Lab Haematol. 2003 Feb;25(1):41-6.

PMID:
12542441
[PubMed - indexed for MEDLINE]
14.

Prognostic factors for multiple myeloma.

Reibnegger G, Fuchs D, Wachter H.

Blood. 1994 Aug 15;84(4):1350-1. No abstract available.

PMID:
8049453
[PubMed - indexed for MEDLINE]
Free Article
15.

Serum oncostatin M in multiple myeloma: association with prognostic factors.

Koskela K, Pelliniemi TT, Remes K, Rajamäki A, Pulkki K.

Br J Haematol. 1997 Jan;96(1):158-60.

PMID:
9012701
[PubMed - indexed for MEDLINE]
16.

Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis.

Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi TT.

Br J Haematol. 1994 Feb;86(2):391-3.

PMID:
8199033
[PubMed - indexed for MEDLINE]
17.

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.

Kyrtsonis MC, Dedoussis G, Zervas C, Perifanis V, Baxevanis C, Stamatelou M, Maniatis A.

Br J Haematol. 1996 May;93(2):398-400.

PMID:
8639436
[PubMed - indexed for MEDLINE]
18.

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.

Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA.

Blood. 1993 Jun 15;81(12):3382-7.

PMID:
8507875
[PubMed - indexed for MEDLINE]
Free Article
19.

Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.

Schambeck CM, Bartl R, Höchtlen-Vollmar W, Wick M, Lamerz R, Fateh-Moghadam A.

Am J Clin Pathol. 1996 Jul;106(1):64-8.

PMID:
8701935
[PubMed - indexed for MEDLINE]
20.

New prognostic factors in multiple myeloma.

Bettini R, Rapazzini P, Marrapodi E.

Haematologica. 1987 Jan-Feb;72(1):102-3. No abstract available.

PMID:
3108088
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk